While reinforcing the importance of treating all known risk factors that contribute to atherosclerotic cardiovascular disease, ASCVD, physicians also need to recognize and treat systemic inflammation in CV disease, according to Dr. Quigley, who addresses the importance of identifying and reducing residual inflammatory risk.

Related Keywords

United States , American , Robertl Quigley , Acta Pharmacologica Sinica , Coll Cardiol , A Report From The American Heart Association , Elsevier , Jefferson Health System Phil , International Corporate Health Leadership Council , Drug Administration , American Heart Association , Jefferson Medical College , Residual Inflammatory , Trials Support Impact , Americas Region , Jefferson Health System , Jefferson Medical , Primary Prevention , Cardiovascular Disease , American College , American Heart Association Task Force , Clinical Practice Guidelines , Cardiovascular Diseases , Risk Factors , Update From , Accessed November , Major Adverse Cardiovascular Events , Patients With Established Atherosclerotic Disease , Multiple Risk , Report From , Dose Colchicine , Secondary Prevention , Coronary Artery Disease , Residual Inflammatory Risk , Shifting Paradigm , Front Cardiovasc , Inflammatory Disease , Common Anti Inflammatory Therapy , How Human Genetics Can Help , Systemic Lupus , Curr Atheroscler , Reactive Protein , Reducing Inflammation , Reduce Atherothrombotic Risk , Published January , Common Is Residual Inflammatory , Yao Hui , Chronic Coronary , Low Dose Colchicine , Statement Regarding , Long Term Low Dose Colchicine ,